The identification of biomarkers such as tumor mutational burden (TMB),6 microsatellite instability (MSI),7 and programmed death-ligand 1 (PD-L1) expression,8 highlights the immunogenic potential of cervical cancer and the rationale for IO-based approaches. The gene discussed is CD274; the disease is cervical cancer.